These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16217747)

  • 1. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
    Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
    Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
    Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
    Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expressions associated with chemosensitivity in human hepatoma cells.
    Hoshida Y; Moriyama M; Otsuka M; Kato N; Taniguchi H; Shiratori Y; Seki N; Omata M
    Hepatogastroenterology; 2007 Mar; 54(74):489-92. PubMed ID: 17523305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays.
    Kang HC; Kim IJ; Park JH; Shin Y; Ku JL; Jung MS; Yoo BC; Kim HK; Park JG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):272-84. PubMed ID: 14734480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene signature-based prediction of tumor response to cyclophosphamide.
    Korrat A; Greiner T; Maurer M; Metz T; Fiebig HH
    Cancer Genomics Proteomics; 2007; 4(3):187-95. PubMed ID: 17878522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting cancer drug response by proteomic profiling.
    Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
    Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
    Januchowski R; Zawierucha P; Ruciński M; Zabel M
    Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
    Işeri OD; Kars MD; Arpaci F; Gündüz U
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):447-55. PubMed ID: 19543729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
    Liedtke C; Wang J; Tordai A; Symmans WF; Hortobagyi GN; Kiesel L; Hess K; Baggerly KA; Coombes KR; Pusztai L
    Breast Cancer Res Treat; 2010 Jun; 121(2):301-9. PubMed ID: 19603265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.
    Quintieri L; Fantin M; Vizler C
    Adv Exp Med Biol; 2007; 593():95-104. PubMed ID: 17265720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
    Kars MD; Işeri OD; Gündüz U
    Eur J Pharmacol; 2011 Apr; 657(1-3):4-9. PubMed ID: 21320484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines.
    Takahashi T; Saikawa Y; Nakamura R; Kumagai K; Takeuchi H; Kubota T; Kitagawa Y
    Oncol Rep; 2009 Feb; 21(2):451-9. PubMed ID: 19148522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
    Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
    Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.